Oncology

A new platform watches individual tumor cells to link behavior with biology, offering a powerful tool against treatment resistance in cancers like glioblastoma.

Interim trial data shows IPH5201 plus durvalumab yields pathological complete response rates up to 50%, far surpassing current standards for resectable NSCLC.

Interim study results suggest a common food product may significantly enhance the effectiveness of modern cancer treatments, heralding a new era of care.

New guidelines advise biennial screening for women 50-74 and caution for others, a move that has drawn sharp criticism from other medical bodies.

With global regulatory approvals secured, Gilead extends its tender offer for Arcellx, moving closer to acquiring a potential best-in-class CAR T therapy.

Preliminary Q1 data from Auna shows rising demand for specialized care in Peru, Colombia, and Mexico, offering investors a transparent new look.

A Korean biotech unveils a breakthrough by targeting the tumor's protective environment, a move that could make existing cancer drugs effective again.

San Diego's Blacksmith Medicines will present promising data on its FEN1 inhibitor, a new drug targeting a notoriously difficult class of enzymes.

A new partnership combines live biopsy analysis with agentic AI, seeking to predict immunotherapy response and solve why only 1 in 5 patients benefit.

Former BCBS CEO Dr. Craig Samitt joins Enlace Health's board, signaling a major push to control the high costs of specialty care with new technology.

A new oral therapy shows a 76% response rate in a hard-to-treat lung cancer, offering a powerful new first-line option for patients with this rare disease.

With founder Frédéric Mascha as Executive Chairman and new CEO Renaud Sermondade, Juvisé Pharmaceuticals is poised for major M&A-fueled global expansion.

A new Finnish startup has launched with a tech that could detect cancer years earlier by amplifying protein signals, aiming to shift healthcare to prevention.

Shanghai's SinoUnited Health is attracting global patients with advanced care like CAR-T therapy at a fraction of US prices, challenging medical tourism hubs.

A new fund, led by a lung cancer survivor and top radiologists, seeks to overhaul screening guidelines that currently miss thousands of at-risk patients.

A groundbreaking study using single-molecule sequencing has revealed how key proteins malfunction in cancer, paving the way for new treatment strategies.

As scientific innovation in oncology accelerates, a new bottleneck emerges: bringing discoveries to market. Specialized firms are now crucial guides.

Taiwanese biotech GlycoNex will begin human trials for GNX1021, a novel ADC that targets cancer's unique sugar coating to fight GI tumors.

Renaissance Pharma's Daretabart gains FDA support for high-risk neuroblastoma, accelerating its journey to patients and offering new hope against this rare disease.

With oral cancer on the rise, especially in younger adults, 49 surgical practices are offering free screenings. Here's why early detection is critical.